239 related articles for article (PubMed ID: 12090463)
1. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
Ganea D; Delgado M
Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
Ganea D; Delgado M
Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Delgado M; Ganea D
J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
Delgado M; Leceta J; Gomariz RP; Ganea D
J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
7. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
8. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Ganea D; Delgado M
Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
[TBL] [Abstract][Full Text] [Related]
9. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression.
Delgado M; Leceta J; Sun W; Gomariz RP; Ganea D
Ann N Y Acad Sci; 2000; 921():68-78. PubMed ID: 11193881
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
12. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors.
Delgado M; Ganea D
Arch Physiol Biochem; 2001 Oct; 109(4):372-6. PubMed ID: 11935376
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Ganea D; Rodriguez R; Delgado M
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Delgado M; Ganea D
J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
[TBL] [Abstract][Full Text] [Related]
15. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
Gonzalez-Rey E; Varela N; Chorny A; Delgado M
Curr Pharm Des; 2007; 13(11):1113-39. PubMed ID: 17430175
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Delgado M; Ganea D
J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
18. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
19. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
20. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
Delgado M; Gonzalez-Rey E; Ganea D
FASEB J; 2004 Sep; 18(12):1453-5. PubMed ID: 15231725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
